ClinicalTrials.gg
CompletedNCT05256654PROLONG-ANG3Updated Mar 17, 2025Results posted

A Study of LY3561774 in Participants With Mixed Dyslipidemia

A Phase 2 interventional study of LY3561774 and Placebo in Dyslipidemias, Lipid Metabolism Disorders and Metabolic Diseases, sponsored by Eli Lilly and Company. Completed at 41 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Primary conditionHyperlipoproteinemiasRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hyperlipoproteinemias
Why
  1. The study's listed conditions name Hyperlipoproteinemias, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.

02

Conditions studied

  • Dyslipidemias
  • Lipid Metabolism Disorders
  • Metabolic Diseases
  • Hyperlipoproteinemia

Keywords

  • Triglycerides
  • LDL Cholesterol
  • Mixed Dyslipidemia
03

In context

Hyperlipoproteinemias Reclassified

35 studies on the registry are indexed under Hyperlipoproteinemias; 6 are open to participants now.

This study's enrollment of 205 is above the median of 84 across 29 interventional studies indexed under Hyperlipoproteinemias.

Browse Hyperlipoproteinemias studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Hyperlipoproteinemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have fasting triglycerides (TGs) within the range of 150 (1.69 millimole/liter (mmoL) to 499 milligram/deciliter (mg/dL) 2.26 to 5.64 millimole/liter (mmol/L) at screening.
  • Have fasting LDL-C ≥70 mg/dL (1.81 mmol/L) at screening.
  • Have non-HDL-C ≥ 130 mg/dL (3.36 mmol/L) at screening.
  • Must be on a stable moderate or high-intensity dose of a statin for at least 2 months before screening and remain on the same medication and dose for the duration of the study.
  • Have a within the range of 18.5 to 40.0 kilogram/square meter (kg/m²), inclusive

Exclusion criteria

Exclusion Criteria:

  • Have in the 6 months prior to screening, uncontrolled Type 1 or Type 2 diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization, or have an (HbA1c) ≥8% at screening.
  • Have a history of nephrotic syndrome.
  • Have a history of acute or chronic pancreatitis.
  • Have had within the past 3 months prior to screening

    • Myocardial infarction
    • Unstable angina
    • Coronary artery bypass graft
    • Percutaneous coronary intervention - diagnostic angiograms are permitted
    • Peripheral artery disease
    • , or
    • Cerebrovascular accident
  • Have Class III or IV heart failure or last known \<30%.
  • Have undergone LDL apheresis within 12 months prior to screening.
  • Have anemia, as defined by the investigator.
  • Have, within 1 year prior to screening or plan on having during the study, surgical treatment for obesity.
  • Have within 3 years prior to screening a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse.
  • Have uncontrolled hypertension.
  • Have used or are taking products for the purpose of lowering lipid levels (except for statins, PCSK9 inhibitors, bempedoic acid, and ezetimibe). This includes lipid-regulating medication, over-the-counter products, or herbal therapies.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    LY3561774 100 mg

    Participants received 100 milligram (mg) LY3561774 subcutaneously (SC) on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.

    Drug: LY3561774

  • Experimental
    LY3561774 400 mg

    Participants received 400 mg LY3561774 SC on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.

    Drug: LY3561774

  • Experimental
    LY3561774 800 mg

    Participants received 800 mg LY3561774 SC on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.

    Drug: LY3561774

  • Placebo comparator
    Placebo

    Participants received placebo SC on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: Solbinsiran

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180

    Change in apoB levels from baseline to Day 180 expressed as a percentage of the baseline levels. Least Square Mean (LS mean) using Mixed Model for Repeated Measures (MMRM) model adjusted for baseline.

    Time frame: Baseline, Day 180

Secondary outcomes

  1. Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) at Day 180

    Change in ANGPTL3 levels from baseline to Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 180

  2. Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) at Day 180

    Change in LDL-C levels from baseline to the day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 180

  3. Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Day 180

    Change in HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 180

  4. Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Day 180

    Change in non-HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 180

  5. Percent Change From Baseline for Triglycerides at Day 180

    Change in triglycerides levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 180

  6. Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3)

    Change in ANGPTL3 levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 270

  7. Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

    Change in non-HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 270

  8. Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C)

    Change in HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 270

  9. Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)

    Change in LDL-C levels from baseline to the day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 270

  10. Percent Change From Baseline for Apolipoprotein B (ApoB)

    Change in apoB levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS mean using MMRM model adjusted for baseline.

    Time frame: Baseline, Day 270

  11. Percent Change From Baseline for Triglycerides

    Change in triglycerides levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

    Time frame: Baseline, Day 270

  12. Pharmacokinetics (PK): Seady State Area Under the Concentration Curve From Hour 0 Extrapolated to Infinity (AUC 0-∞) of LY3561774

    PK: Seady State AUC (0-∞) of LY3561774

    Time frame: On Day 0: 0.5 hour (hr) and at the latest time after 2 hr post-dose, Day 90: 24 to 48 hr postdose

07

Results

Posted Mar 17, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Started58305859
Received at least 1 dose of study drug57305859
Completed57275554
Not completed1335
Withdrew: Adverse event0010
Withdrew: Lost to follow-up0001
Withdrew: Withdrawal by subject1213
Withdrew: Earthquake at the turkey site prevented participation in the study0110
Withdrew: Other0001

Outcome measures

PrimaryPercent Change From Baseline for Apolipoprotein B (ApoB) at Day 180

Change in apoB levels from baseline to Day 180 expressed as a percentage of the baseline levels. Least Square Mean (LS mean) using Mixed Model for Repeated Measures (MMRM) model adjusted for baseline.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180-11.6 ± 3.65-14.1 ± 4.98-24.3 ± 3.10-19.0 ± 3.35
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.691 · Mean difference (net): -2.8 · 95% CI -15.5 to 11.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (Triglycerides (TG) \<250 milligram per deciliter (mg/dL) or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = 0.008 · Mean difference (net): -14.3 · 95% CI -23.6 to -3.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = 0.140 · Mean difference (net): -8.3 · 95% CI -18.3 to 2.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) at Day 180

Change in ANGPTL3 levels from baseline to Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) at Day 180
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) at Day 180-3.2 ± 6.22-55.7 ± 4.01-70.8 ± 1.86-77.3 ± 1.46
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -54.3 · 95% CI -63.3 to -43.1Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -69.8 · 95% CI -74.8 to -63.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -76.6 · 95% CI -80.4 to -72.0Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) at Day 180

Change in LDL-C levels from baseline to the day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) at Day 180
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) at Day 180-8.7 ± 3.87-9.9 ± 5.39-24.0 ± 3.21-19.7 ± 3.42
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.854 · Mean difference (net): -1.3 · 95% CI -14.6 to 14.0Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = 0.002 · Mean difference (net): -16.8 · 95% CI -26.0 to -6.4Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = 0.033 · Mean difference (net): -12.1 · 95% CI -21.9 to -1.1Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Day 180

Change in HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Day 180
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Day 1804.3 ± 2.59-2.1 ± 3.43-12.8 ± 2.15-19.4 ± 2.00
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.143 · Mean difference (net): -6.1 · 95% CI -13.8 to 2.2Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -16.4 · 95% CI -22.0 to -10.5Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -22.7 · 95% CI -27.9 to -17.2Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Day 180

Change in non-HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Day 180
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Day 180-10.2 ± 3.24-19.8 ± 4.06-33.1 ± 2.41-31.5 ± 2.47
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.068 · Mean difference (net): -10.8 · 95% CI -21.1 to 0.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -25.5 · 95% CI -32.6 to -17.6Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -23.8 · 95% CI -31.1 to -15.7Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Triglycerides at Day 180

Change in triglycerides levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 180
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Triglycerides at Day 180
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Triglycerides at Day 180-15.1 ± 4.01-45.9 ± 3.61-57.8 ± 1.98-59.7 ± 1.90
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -36.3 · 95% CI -45.8 to -25.1Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -50.3 · 95% CI -56.4 to -43.3Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -52.5 · 95% CI -58.4 to -45.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3)

Change in ANGPTL3 levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3)
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3)-17.0 ± 6.00-49.0 ± 5.28-61.9 ± 2.75-69.8 ± 2.19
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -38.6 · 95% CI -52.2 to -21.2Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -54.0 · 95% CI -62.4 to -43.8Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -63.6 · 95% CI -70.3 to 55.5Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Change in non-HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)-9.8 ± 3.22-13.5 ± 4.44-27.6 ± 2.56-27.3 ± 2.59
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.506 · Mean difference (net): -4.1 · 95% CI -15.2 to 8.5Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -19.7 · 95% CI -27.2 to -11.3Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -19.4 · 95% CI -27.0 to -11.0Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C)

Change in HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C)
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C)1.5 ± 2.48-1.9 ± 3.48-7.3 ± 2.24-10.9 ± 2.18
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.428 · Mean difference (net): -3.4 · 95% CI -11.2 to 5.2Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = 0.009 · Mean difference (net): -8.7 · 95% CI -14.7 to -2.3Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -12.2 · 95% CI -18.0 to -6.0Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)

Change in LDL-C levels from baseline to the day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)-12.7 ± 3.78-7.1 ± 5.81-21.0 ± 3.39-17.5 ± 3.57
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.412 · Mean difference (net): 6.5 · 95% CI -8.4 to 23.7Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = 0.104 · Mean difference (net): -9.5 · 95% CI -19.7 to 2.1Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = 0.363 · Mean difference (net): -5.4 · 95% CI -16.2 to 6.7Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Apolipoprotein B (ApoB)

Change in apoB levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS mean using MMRM model adjusted for baseline.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Apolipoprotein B (ApoB)
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Apolipoprotein B (ApoB)-9.5 ± 3.57-19.2 ± 4.61-19.7 ± 3.18-19.4 ± 3.20
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = 0.101 · Mean difference (net): -10.8 · 95% CI -22.2 to 2.3Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = 0.033 · Mean difference (net): -11.3 · 95% CI -20.6 to -1.0Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = 0.040 · Mean difference (net): -10.9 · 95% CI -20.3 to -0.6Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPercent Change From Baseline for Triglycerides

Change in triglycerides levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · Percent change
Percent Change From Baseline for Triglycerides
Percent changePlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Percent Change From Baseline for Triglycerides-13.9 ± 4.63-38.3 ± 4.80-50.5 ± 2.63-52.5 ± 2.55
Statistical analysis
  • Placebo vs LY3561774 100 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -28.3 · 95% CI -40.5 to -13.6Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 400 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -42.5 · 95% CI -50.5 to -33.2Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
  • Placebo vs LY3561774 800 mg · Mixed Models Analysis · p = <.001 · Mean difference (net): -44.8 · 95% CI -52.5 to -35.9Model uses log-transformed outcome and baseline variables, including terms for baseline, strata (TG \<250 mg/dL or \>=250 mg/dL at screening), and the interaction between treatment and time.
SecondaryPharmacokinetics (PK): Seady State Area Under the Concentration Curve From Hour 0 Extrapolated to Infinity (AUC 0-∞) of LY3561774

PK: Seady State AUC (0-∞) of LY3561774

Time frame:
On Day 0: 0.5 hour (hr) and at the latest time after 2 hr post-dose, Day 90: 24 to 48 hr postdose
Reported as:
Geometric mean · nanogram.hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Seady State Area Under the Concentration Curve From Hour 0 Extrapolated to Infinity (AUC 0-∞) of LY3561774
nanogram.hour per milliliter (ng*h/mL)LY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Pharmacokinetics (PK): Seady State Area Under the Concentration Curve From Hour 0 Extrapolated to Infinity (AUC 0-∞) of LY35617746979 ± 3525045 ± 2461306 ± 43

Adverse events

Collected over Baseline up to 360 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/57 (0%)5/57 (8.8%)16/57 (28.1%)
LY3561774 100 mg0/30 (0%)1/30 (3.3%)14/30 (46.7%)
LY3561774 400 mg0/58 (0%)3/58 (5.2%)14/58 (24.1%)
LY3561774 800 mg0/59 (0%)2/59 (3.4%)9/59 (15.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Radius fractureInjury, poisoning and procedural complications2/570/300/580/59
CellulitisInfections and infestations0/571/300/580/59
Angina pectorisCardiac disorders1/570/300/580/59
PneumoniaInfections and infestations1/570/300/581/59
HypocalcaemiaMetabolism and nutrition disorders1/570/300/580/59
Brain abscessInfections and infestations0/570/301/580/59
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/570/301/580/59
Pelvic venous thrombosisVascular disorders0/570/301/580/59
CholelithiasisHepatobiliary disorders0/570/300/581/59
Pneumonia viralInfections and infestations0/570/300/581/59
Most frequent other events
Most frequent other events
EventPlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mg
Covid-19Infections and infestations4/574/303/582/59
GastroenteritisInfections and infestations3/573/302/580/59
InfluenzaInfections and infestations0/572/302/582/59
Pancreatic enzymes increasedInvestigations0/572/301/581/59
HypertensionVascular disorders2/572/301/582/59
NasopharyngitisInfections and infestations3/571/303/582/59
Urinary tract infectionInfections and infestations3/571/301/581/59
Lipase increasedInvestigations3/570/301/580/59
Injection site reactionGeneral disorders0/571/303/581/59

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)PlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mgTotal
Mean55.50 ± 11.6158.40 ± 10.9756.40 ± 11.9757.30 ± 10.6156.70 ± 11.30
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mgTotal
Female35182929111
Male2312293094
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mgTotal
Hispanic or Latino36203944139
Not Hispanic or Latino228191564
Unknown or Not Reported02002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mgTotal
American Indian or Alaska Native2111142268
Asian11610936
Native Hawaiian or Other Pacific Islander00000
Black or African American10001
White25133428100
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)PlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mgTotal
Argentina158211862
Canada547218
Japan747725
Mexico2112182677
Poland30115
Turkey323311
United States40127
Baseline Apolipoprotein B (ApoB)
Baseline Apolipoprotein B (ApoB)(milligram per deciliter (mg/dL))PlaceboLY3561774 100 mgLY3561774 400 mgLY3561774 800 mgTotal
Median111 (23 to 246)109.50 (49 to 186)112 (73 to 169)114 (52 to 205)111 (23 to 246)
08

Study locations

41 sites
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aire, Buenos Air C1027AAP, Argentina
  • Glenny Corp
    Buenos Aires, Ciudad Aut C1430CKE, Argentina
  • CIPREC
    Caba, Ciudad Aut C1061AAS, Argentina
  • Investigaciones Medicas Imoba Srl
    Buenos Aires, Ciudad Autónoma De Buenos Aire C11056ABF, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aire C1425AGC, Argentina
  • Sanatorio San Martin
    Venado Tuerto, Santa Fe 2600, Argentina
  • Fundación Respirar
    Buenos Aires, C1426ABP, Argentina
  • Clínica Privada Velez Sarsfield
    Córdoba, 5016, Argentina
  • Centro de Investigaciones Clinicas Instituto del Corazon (CICIC)
    Córdoba, X5002HWE, Argentina
  • Centro de Investigaciones Clinicas del Litoral
    Santa Fe, S3000FWO, Argentina
  • OCT Research ULC
    Kelowna, British Columbia V1Y 1Z9, Canada
  • North York Diagnostic and Cardiac Centre
    North York, Ontario M6B 3H7, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Viacar Recherche Clinique
    Greenfield Park, Quebec J4V 2G8, Canada
  • Clinique des Maladies Lipidiques de Québec
    Québec, Quebec G1V 4W2, Canada
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Medical Corporation Chiseikai Tokyo Center Clinic
    Chuo-ku, Tokyo 103-0028, Japan
  • Heishinkai Medical Group ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • AMC Nishiumeda Clinic
    Osaka, 530-0001, Japan
  • Virgen Cardiovascular Research SC
    Guadalajara, Jalisco 44670, Mexico
  • Cardiolink Clin Trials
    Monterrey, Nuevo León 64060, Mexico
  • Unidad Médica para la Salud Integral
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Medical Care and Research SA de CV
    Merida, Yucatán 97070, Mexico
  • Investigacion En Salud Y Metabolismo Sc
    Chihuahua, 31217, Mexico
  • NZOZ Centrum Medyczne KERmed
    Bydgoszcz, Kujawsko-p 85-231, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie
    Warsaw, Mazowieckie 02-097, Poland
  • Niepubliczny Zakład Opieki Zdrowotnej "Przychodnia z Sercem"
    Grojec, Małopolskie 32-615, Poland
  • Centrum Zdrowia Tuchów
    Wierzchosławice, Małopolskie 33-122, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o.
    Gdansk, Pomorskie 80-546, Poland
  • Ege Universitesi Hastanesi
    Bornova, İzmir 35100, Turkey
  • Necmettin Erbakan Meram Medical Fac.
    Meram, Konya 42080, Turkey
  • Akdeniz Universitesi Hastanesi
    Antalya, 07070, Turkey
  • Istanbul University Cerrahpasa Medical School Internal Diseases Institute
    Istanbul, 34096, Turkey
  • Kocaeli Üniversitesi
    Kocaeli, 41380, Turkey
  • Mersin University
    Mersin, 33343, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Mar 2024, 19 months.

Results were first posted in Mar 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2022
First posted
Feb 25, 2022
StartActual
Jul 20, 2022
Primary completionActual
Mar 4, 2024
CompletionActual
May 23, 2024
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05256654
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Jul 20, 2022
Primary completion
Mar 4, 2024
Completion
May 23, 2024
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solbinsiran

Start the discussion